Patients with AML and MDS presenting cytogenetic abnormalities associated with unfavorable risk, TP53 mutations, or both had favorable clinical responses and robust (but incomplete) mutation clearance after receiving serial 10-day courses of decitabine. Here, TP53 is linked to myelodysplastic syndrome.